Dual inhibiting EGFR and VEGF pathways versus EGFR-TKIs alone in the treatment of advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials

被引：0
|
作者：
T. T. Zhang
R. M. Wang
Z. Yang
G. B. Chen
机构：
[1] The First People’s Hospital of Shangqiu,Department of Oncology
[2] The First People’s Hospital of Shangqiu,Department of General Surgery
[3] The First Affiliated Hospital of Zhengzhou University,Department of Gastrointestinal Surgery
来源：
Clinical and Translational Oncology | 2016年 / 18卷
关键词：
Non-small-cell lung cancer; EGFR-TKIs; Molecular targeted agents; Angiogenesis inhibitors; Meta-analysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：576 / 581
页数：5
相关论文
共 50 条
  • [1] Dual inhibiting EGFR and VEGF pathways versus EGFR-TKIs alone in the treatment of advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials
    Zhang, T. T.
    Wang, R. M.
    Yang, Z.
    Chen, G. B.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2016, 18 (06) : 576 - 581
  • [2] Incidence and risk of infections associated with EGFR-TKIs in advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized controlled trials
    Wang, Yingtian
    Wang, Mingzhen
    Wang, Qiaoxia
    Geng, Zhiying
    Sun, Mingxiang
    ONCOTARGET, 2017, 8 (17) : 29406 - 29415
  • [3] Efficacy of Next-Generation EGFR-TKIs in Patients With Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials
    Qi, Yi-Tian
    Hou, Yi
    Qi, Liang-Chen
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2020, 19
  • [4] EGFR tyrosine kinase inhibitors alone or in combination with chemotherapy for non-small-cell lung cancer with EGFR mutations: A meta-analysis of randomized controlled trials
    Zhu, Cui-Min
    Lian, Xiang-Yao
    Zhang, Hong-Yan
    Bai, Lu
    Yun, Wen-Jing
    Zhao, Ru-Han
    Li, Qing-Shan
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2021, 17 (03) : 664 - 670
  • [5] Risk of interstitial lung disease associated with EGFR-TKIs in advanced non-small-cell lung cancer: a meta-analysis of 24 phase III clinical trials
    Qi, Wei-Xiang
    Sun, Yuan-Jue
    Shen, Zan
    Yao, Yang
    JOURNAL OF CHEMOTHERAPY, 2015, 27 (01) : 40 - 51
  • [6] Efficacy and safety of osimertinib plus bevacizumab versus osimertinib alone for advanced non-small-cell lung cancer with EGFR mutations: A meta-analysis of randomized controlled trials
    Yao, Ling
    Zhang, Chunzhen
    Li, Dailong
    Xu, Lu
    Yang, Xianfei
    MEDICINE, 2024, 103 (45) : e40320
  • [7] A meta-analysis of adjuvant EGFR-TKIs for patients with EGFR mutation of resected non-small cell lung cancer
    Cui, Ran
    Wei, Chun
    Li, Xianyi
    Jiang, Ou
    MEDICINE, 2022, 101 (47) : E31894
  • [8] Third generation vs first generation EGFR-TKIs in the first line treatment for EGFR-mutated locally advanced or metastatic non-small cell lung cancer: a meta-analysis based on randomized controlled trials
    Hu, Wenjie
    Qin, Yi
    Dong, Taoming
    Lin, Xueying
    Chen, Yuan
    Zhang, Wenxiong
    Feng, Tanggui
    JOURNAL OF CANCER, 2025, 16 (03): : 735 - 747
  • [9] Comparative Outcome Assessment of EGFR TKIs for the Treatment of Advanced Non-Small-Cell Lung Cancer: A Network Meta-Analysis
    De Mello, Ramon Andrade
    Aguiar, Pedro, Jr.
    Cabral, Paloma
    Chaves, Fablo
    Liu, Davi
    Soares, Joao Paulo
    Mountzios, Giannis
    Tadokoro, Hakaru
    Lopes, Gilberto De Lima
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1239 - S1240
  • [10] Impact of Sex and Smoking on the Efficacy of EGFR-TKIs in Terms of Overall Survival in Non-small-Cell Lung Cancer: A Meta-Analysis
    Xiao, Jian
    Zhou, Liang
    He, Bixiu
    Chen, Qiong
    FRONTIERS IN ONCOLOGY, 2020, 10
12345